UnitedHealth Group (UNH) Responds to the Department of Justice
A senior healthcare professional giving advice to a patient in a clinic.
UnitedHealth Group Incorporated (NYSE:UNH) stated that it has now begun complying with the formal criminal and civil requests from the Department, and has 'full confidence in its practices and is committed to working cooperatively with the Department throughout this process'.
It added that UnitedHealth Group Incorporated (NYSE:UNH) has a historical record of 'responsible conduct and effective compliance,' with independent CMS audits showing that its practices are ranked 'among the most accurate in the industry.'
Management stated that after a decade-long civil challenge by the Department to aspects of the company's Medicare Advantage business, 'a court-appointed Special Master concluded there was no evidence to support claims of wrongdoing'.
UnitedHealth Group Incorporated (NYSE:UNH) has launched its own initiative to provide confidence and transparency to stakeholders, focusing on conducting 'third-party reviews of policies, practices, and associated processes and performance metrics for risk assessment coding, managed care practices, and pharmacy services.'
UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare coverage, data consultancy, and software services. It operates through the OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare segments, which have solid operations.
While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
UnitedHealth Group reports mixed second quarter earnings; stock down in premarket trading
UnitedHealth Group (UNH) reported second quarter earnings Tuesday, beating Wall Street's expectations on the top line by a small margin and missing on the bottom line. But its earnings continue a trend of higher-than-expected costs in the industry this quarter. The company reported revenues of $111.6 billion, compared to Wall Street expectations of $111.53 billion, and adjusted earnings per share (EPS) of $4.08, compared to $4.59 expected by the Street. Revenues are up nearly $13 billion year over year compared to the second quarter in 2024. But margins have shrunk from 4.3% in 2024 to 3.1% this quarter. The company also updated its guidance for the full year after pulling it last quarter. It now expects revenues between $445.5 and $448.0 billion and adjusted earnings of at least $16 per share. UnitedHealth's stock fell more than 5% in trading Tuesday. Read more: Live coverage of corporate earnings Industry pressure More patients seeking care means more premiums being paid out and less revenue for health insurers. Typically, insurers aim to be on the lower end of between 80% and 85% of the premiums they receive, known as the medical expense ratio. UnitedHealth reported 89.4% this quarter, compared to 84.8% in the first. That number is the highest in the company's history, breaking its 2024 record of 85.5%, which was attributed to higher utilization of care by seniors. Other insurers have reported 90% or more in the second quarter this year — a significant jump from prior quarters, and it's all related to Medicare or Medicaid programs. This marks a continuing trend that has been plaguing the industry since last year and has taken several stocks for a ride every quarter. Notably, CVS (CVS) saw a hit to its stock after its Aetna Medicare costs came in higher than expected, but then its stock was boosted last quarter as fears of costs were allayed. This quarter, Centene (CNC) and Elevance (ELV) have faced higher-than-expected costs. The hit to UnitedHealth on Tuesday appears to be a delayed part of that trend — and the company has acknowledged that it, like other big insurers, is surprised by the hit. Especially with the company's focus on revenue management, owning and acquiring companies over the years would rely on technology to streamline and increase profits. The result of the inaccurate cost assumptions will be felt by patients next year, as UnitedHealth announced it will exit several markets, impacting 600,000 patients. That's in the Medicare Advantage market alone. It also anticipates heavy losses in the Affordable Care Act marketplace, as enhanced subsidies from the pandemic expire. On top of which, premiums are likely to rise next year as the company looks to boost revenues and profits. Industry change In addition to the insurance market woes, UnitedHealth has faced internal struggles. Former CEO Andrew Witty was ousted in May. Former CEO and board chair Stephen Hemsley then took the helm. The executive shake-up came after a year of turmoil for the company, including the largest-ever cyberattack on its Change Healthcare subsidiary. Meanwhile, the company is still reeling from the death of insurance executive Brian Thompson, who was shot and killed in New York City last year. The incident prompted an awakening in the insurance industry, which faced a backlash for its system of prior authorization requirements that result in denials of care. Several companies and the Trump administration have pledged to fix the problems and relax prior authorization burdens for patients. Humana executives said last week during an earnings call that the company would reduce prior authorizations by one-third of the current volume. UnitedHealth previously said that it only sees prior authorizations for 2% of total claims and that it will further reduce that amount. UnitedHealth said Tuesday the company is focused on greater transparency with Hemsley leading and expects to continue offering greater insight into its operations as it rebuilds the company. 'UnitedHealth Group has embarked on a rigorous path back to being a high-performing company fully serving the health needs of individuals and society broadly,' CEO Stephen Hemsley said in a statement. 'As we strengthen operating disciplines, positioning us for growth in 2026 and beyond, the people at UnitedHealth Group will continue to support the millions of patients, physicians and customers who rely on us, guided by a culture of service and longstanding values.' Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem.
Fast Company
42 minutes ago
- Fast Company
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
Health-related stocks are not having a good day. First, America's largest health insurance provider, UnitedHealth Group (NYSE: UNH), saw its stock drop more than 4% this morning after the company announced disappointing second-quarter results and a full-year 2025 forecast that concerned investors. And now, the Danish pharmaceutical giant Novo Nordisk A/S, whose shares (NYSE: NVO) trade on the New York Stock Exchange, is seeing its stock price plunge, too. Currently, NVO shares are down more than 20% at the time of this writing. But unlike UnitedHealth Group, Novo Nordisk has not reported its most recent quarterly results. So what's sending its shares lower? Here's what you need to know. Novo Nordisk cuts full-year 2025 guidance The main driver of Novo Nordisk's significant share price fall today is the company's announcement that it is revising its previously published sales growth and operating profit growth for its full fiscal year 2025. On May 7, Novo Nordisk stated that it expected full-year fiscal 2025 sales growth to be between 13% and 21%. At the same time, it said it expected its operating profit growth to be between 16% and 24%. Now, however, the company had drastically cut both forecasts. Novo Nordisk now says it expects full-year fiscal 2025 sales growth to be between 8% and 14% and operating profit growth to be between 10% and 16%. In a statement, the company said its 'lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025.' This lowered growth is due to lower growth expectations for its GLP-1 weight loss and diabetes drugs, Wegovy and Ozempic, in the U.S. market. 'For Wegovy in the US, the sales outlook reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition,' the company said. It added that as far as Ozempic was concerned, 'the updated outlook is negatively impacted by competition in the U.S.' Novo Nordisk's main competitor in the GLP-1 arena is the American pharmaceutical giant Eli Lilly, who makes the drugs Mounjaro and Zepbound. Novo Nordisk names new CEO Besides revising its 2025 growth forecasts downward, Novo Nordisk also made another announcement today: It named a new CEO. However, this announcement probably had little to do with the stock's fall this morning. Back in May, Novo Nordisk announced that its longtime CEO Lars Fruergaard Jørgensen would be stepping aside. At the time, the company cited its declining share price as one of the reasons for the CEO shakeup. It also said Jørgensen would stay on as CEO until a successor was found. Now, one has been. Today, Novo Nordisk announced that Maziar Mike Doustdar will be assuming the position of president and chief executive officer, effective August 7, 2025. Doustdar is currently the company's executive vice president of international operations. Announcing Doustdar's ascent to the CEO role, Novo Nordisk chair Helge Lund said: 'This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Doustdar will officially take over as CEO one day after the company reports its second quarter 2025 results on August 6. Novo Nordisk shares have fallen dramatically since last summer While the GLP-1 drugs Wegovy and Ozempic have been a massive source of growth and profits at Novo Nordisk in the first half of this decade, recently, the company has faced increased competition in the GLP-1 marketplace, which has partly contributed to investor concerns. Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down more than 57%. And since the beginning of 2025, the company's share price has declined more than 35%.
Axios
42 minutes ago
- Axios
UnitedHealth Group plans "remediation actions" as insurance costs balloon
UnitedHealth Group 's stock continued its year-long descent Tuesday after the insurer warned that escalating medical costs will continue to drag down its earnings. Why it matters: The nation's largest insurer has taken a steep hit in 2025, struggling with several financial challenges while continuing to face public scrutiny for coverage denials and patient expenses. Driving the news: The company reported Tuesday that its medical care ratio soared by 4.3 percentage points to 89.4% in the second quarter as costs "significantly exceeded pricing trends," stemming in part from "the intensity of services delivered, and the ongoing effects of Medicare funding reductions." In other words, patients are using their insurance plans at a much higher rate than expected. The company expects its full-year medical cost ratio to be about 89.25%. Zoom in: UnitedHealth reestablished its earnings outlook after suspending it in May, announcing the sudden exit of CEO Andrew Witty and appointing former CEO Stephen Hemsley to return to the post. The new outlook projects 2025 revenue of $445.5 billion to $448 billion, net earnings per share of at least $14.65 and adjusted earnings per share of at least $16. The company said it won't return to earnings growth until 2026. The outlook showed profit "would be hit harder than Wall Street was expecting," Bloomberg reported, noting the company's "ability to quickly cope with unanticipated, rising expenses is limited" due to the fact that pricing changes only once a year. The impact: UNH shares were down 4.4% Tuesday at 11am ET, and are now down more than 46% on the year. Threat level: Tim Noel, CEO of the company's UnitedHealthcare insurance division, said on a conference call that customers can expect "strongly responsive pricing for 2026" as "we are intensifying our remediation actions." "We have stepped up our audit, clinical policy and payment integrity tools to protect customers and patients from unnecessary costs," he said, adding that the changes will be "grounded in safety and quality while also identifying waste and abuse in outlier coding and billing practices." The company, Noel said, will also be "shifting to narrower networks and focusing on more disciplined, managed products, particularly in Medicare Advantage, and we have scaled our AI efforts across health plan operations, which improves the patient and provider service experiences while driving cost savings."
